Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

BioLineRx (BLRX) EBT Margin (2023 - 2025)

Historic EBT Margin for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 445.67%.

  • BioLineRx's EBT Margin fell 3695600.0% to 445.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 108.68%, marking a year-over-year increase of 904700.0%. This contributed to the annual value of 66.63% for FY2024, which is 9234800.0% up from last year.
  • Per BioLineRx's latest filing, its EBT Margin stood at 445.67% for Q3 2025, which was down 3695600.0% from 666.78% recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's EBT Margin peaked at 2092.06% during Q4 2023, and registered a low of 1376.34% during Q3 2023.
  • In the last 3 years, BioLineRx's EBT Margin had a median value of 262.45% in 2024 and averaged 231.63%.
  • Data for BioLineRx's EBT Margin shows a peak YoY increase of 13002400bps (in 2024) and a maximum YoY decrease of -21596300bps (in 2024) over the last 5 years.
  • BioLineRx's EBT Margin (Quarter) stood at 2092.06% in 2023, then plummeted by -103bps to 67.57% in 2024, then crashed by -560bps to 445.67% in 2025.
  • Its EBT Margin was 445.67% in Q3 2025, compared to 666.78% in Q2 2025 and 772.94% in Q1 2025.